Incannex Healthcare (IXHL) Cash from Financing Activities (2023 - 2026)
Incannex Healthcare (IXHL) posted Cash from Financing Activities of $4.7 million for Q1 2026, up 408.09% sequentially from $927000.0 in Q4 2025, and down 39.18% YoY from $7.7 million in Q1 2025.
Incannex Healthcare (IXHL) Cash from Financing Activities (2023 - 2026) Analysis & Trends
Incannex Healthcare has reported Cash from Financing Activities for 4 years, with the latest figure at $4.7 million in Q1 2026.
- Quarterly Cash from Financing Activities fell 39.18% year-over-year to $4.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $82.4 million (up 600.7% YoY) and the FY2025 annual result came in at $21.4 million, changed N/A from the prior year.
- Cash from Financing Activities grew to $4.7 million in Q1 2026 per IXHL's latest filing, from $927000.0 in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $67.2 million in Q3 2025 and troughed at -$73000.0 in Q1 2023.
- A 4-year average of $10.5 million and a median of $4.1 million in 2024 frame the typical range for Cash from Financing Activities.
- The widest YoY moves for Cash from Financing Activities: up 129286.54% in 2025, down 77.4% in 2025.
- Over 4 years, Cash from Financing Activities stood at -$32000.0 in 2023, then jumped by 12918.75% to $4.1 million in 2024, then slumped by 77.4% to $927000.0 in 2025, then surged by 408.09% to $4.7 million in 2026.
- According to Business Quant data, Cash from Financing Activities over the past three periods registered $4.7 million, $927000.0, and $67.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | -1.00 Mn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | -813.00 Mn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | -1.13 Bn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 122.40 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | -1.24 Bn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | 63.40 Mn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | -74.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Incannex Healthcare | 44.39 Mn | 44.39 Mn | - | 4.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.71 Mn |
| Mar 31, 2026 | 4.71 Mn |
| Dec 31, 2025 | 927,000.00 |
| Dec 31, 2025 | 927,000.00 |
| Sep 30, 2025 | 67.18 Mn |
| Sep 30, 2025 | 67.18 Mn |
| Jun 30, 2025 | 9.60 Mn |
| Jun 30, 2025 | 9.60 Mn |
| Mar 31, 2025 | 7.74 Mn |
| Mar 31, 2025 | 7.74 Mn |
| Dec 31, 2024 | 4.10 Mn |
| Dec 31, 2024 | 4.10 Mn |
| Sep 30, 2024 | -52,000.00 |
| Sep 30, 2024 | -52,000.00 |
| Jun 30, 2023 | -32,000.00 |
| Jun 30, 2023 | -32,000.00 |
| Mar 31, 2023 | -73,000.00 |
| Mar 31, 2023 | -73,000.00 |